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Summary Lymphocytes were studied as vehicles to target the plant toxin ricin, to lymphoid tissue in rats.
Ricin-loaded thoracic duct lymphocyte (TDL) migrated normally into lymph nodes (LN) at 0.5 h, but this
process was arrested by 3 h after injection. Ricin was successfully targeted to lymphoid tissue as evidenced by
a 4-fold increase in ricin-associated radioactivity in LN, a 10-fold increase in the Peyers patches, a doubling in
the spleen and a 35% reduction of radioactivity in the liver compared with free ricin. Nevertheless this
represented a considerable shortfall in the expected targeting efficiency. The main problem was found to be
high in vivo elution of ricin from TDL (70% within 0.5 h of i.v. injection). This and other aspects relevant to
maximising targeting efficiency are discussed.
Ricin, the highly toxic glycoprotein from the castor bean
Ricinus communis, has been studied extensively at both cell-
ular and molecular levels. Binding of the B-chain glyco-
protein to cell surface receptors results in the internalisation
and translocation of toxic A chain to its intracellular site of
action. Ricin A-chain enzymically inhibits protein synthesis
by inactivation of the 60S ribosomal subunit (Sperti et al.,
1973). This is achieved by cleavage of an adenine base
residue from the 28S ribosomal subunit (Endo et al., 1987).
Ricin has been extensively studied as a potential agent for
the treatment of malignancy. When used in laboratory ro-
dents, ricin successfully inhibited growth of Ehrlich ascites
tumour cells (Lin et al., 1970; Fodstad et al., 1977). Adjuvant
therapy with adriamycin significantly enhanced the lifespan
of animals inoculated with leukaemic cells (Fodstad & Pihl,
1980a). Ricin treatment suppressed the growth of human
tumour cell lines growing as xenografts in athymic mice
(Fodstad et al., 1980b,c). More recently Phase 1 clinical trials
have been completed on 54 cancer patients with advanced
disease (Fodstad et al., 1984).
In an attempt to improve the efficacy of ricin therapy,
various methods have been employed to target ricin to
specific sites of action. Immunotoxins have been prepared
linking ricin, either as holotoxin or A-chain, to monoclonal
antibodies against cell surface antigens. This approach has
been utilised in vitro to kill contaminating leukaemic cells
(Kronke et al., 1985; Press et al., 1986; Katz et al., 1987)
from human bone marrow. Ex vivo treatment of bone mar-
row with immunotoxin directed against immunocompetent T
lymphocytes has successfully prevented graft-versus-host
disease in allogeneic recipients (Vallera et al., 1981; Fil-
lipovich et al., 1984).
Another method of targeting is to utilise a migrating
population of cells as vehicles to carry material to a partic-
ular site in the body. Lymphocytes can be used to carry
toxins or radioisotopes to lymphoid tissue (Ford, 1985).
Radiolabelled lymphocytes migrate normally for a variable
period during which time 80%-90% gain access to lymphoid
tissue (Rannie & Donald, 1977; Birch et al., 1986). This
method has been successfully employed to deposit radioactive
isotopes in spleen and lymph nodes (LN) of normal subjects
and patients with lymphoma and leukaemia for diagnostic
purposes (Lavender et al., 1977; Wagstaff et al., 1981a,b).
This is currently being developed at the Christie Hospital,
Manchester, for therapeutic purposes (Hamilton et al., 1988).
Mammalian cells internalise ricin which is later liberated in
a form that is toxic to a second cell population (McIntosh et
al., 1984). Sparshott et al. (1985) demonstrated that lym-
phocytes loaded with ricin and trace-labelled with 51Cr re-
tained their normal migratory characteristics in vivo at early
time intervals following injection. These results based on 5'Cr
localisation, suggested that ricin was delivered in high con-
centrations to lymphoid tissues. The resulting histological
changes of lymphoid destruction observed in spleen and LN
supported this view. Adoptive transfer of lymphocytes bear-
ing ricin successfully inhibited Moloney-murine sarcoma
virus induced tumours in vivo (Cerundolo et al., 1987).
In order to assess the efficiency of ricin targeting by lym-
phocytes the distribution of '25I-ricin on cells was compared
with the distribution of free radioiodinated ricin in vivo. The
aim of the investigation was to develop means of increasing
the ricin concentration in spleen and LN while minimising
localisation to the liver and bone marrow.
Materials and methods
Ricin
The toxin Ricinus communis was prepared from the defatted
castor bean cake according to the procedures described in
detail by Cumber et al. (1985). Ricin was kindly supplied
by Dr A. Forrester and Professor A.J.S. Davies from the
Chester Beatty Cancer Research Laboratory, and at a later
stage by Dr P. Thorpe from the Imperial Cancer Research
Foundation, London.
Radiolabelling ricin holotoxin
Ricin was radioiodinated by a protocol based on the iodogen
method (Johnstone & Thorpe, 1982). Ricin (1.5mgml1' in
PBS) was added to an iodogen tube containing sufficient
powdered lactose, to give a final concentration of 100 mmol.
1 mCi 125I (Amersham, Code NoIMS30, specific activity
approx 16 mCipg- of iodine) was added and incubated on
ice for 1 h. Free 1251 and lactose were separated from '25I-ricin
conjugate on a P6 acrylic column equilibrated with 0.6 M
sodium acetate buffer. Protein concentration was estimated
by spectrometry (LKB Ultrospec 4050) and the specific
radioactivity determined.
Animals
Rats of the highly inbred AO or PVG strains (RT1U and
RT1C respectively) were bred and maintained in the Univer-
sity of Manchester Animal Unit.
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Thoracic duct cannulation
This was performed by Gowan's method (Ford, 1978). Thor-
acic duct lymphocytes (TDL) were collected in heparinised
Dulbecco's phosphate-buffered saline with added mineral
salts either overnight at 0°C or, for not more than 4 h at
room temperature.
'Cr-labelledpassaged TDL
TDL collected 'on ice' and subjected to the in vitro proce-
dures of radiolabelling, temporarily lose their ability to
rapidly migrate into LN (Smith & Ford, 1983). However,
these radiolabelled lymphocytes recover in vivo following i.v.
injection and re-appear in thoracic duct lymph maximally by
approximately 18 h later; such cells are referred to as pas-
saged cells and if collected at room temperature and injected
within a 4 h period retain their ability to rapidly migrate to
LN. Accordingly, an overnight collection of TDL was
washed and resuspended in RPMI medium at 108 cells ml',
incubated with 5"Cr (Amersham, Code No CJS IP, specific
activity 250-500 Ci mg-' chromium) at 10 liCi ml' at 37°C
for 1 h. The cells were washed once, resuspended to approx-
imately 5 x 108 cells ml-' and injected i.v. into thoracic duct-
cannulated intermediate rats. 2-3 x 109 labelled cells (a 20 h
collection from four donor rats) were injected into each
intermediate animal. Approximately 10% of these cells were
recovered in lymph during a 4 h collection the following day.
Ricin-conjugated TDL
Since the dual effect of prolonged collection of TDL and low
temperature interferes with the recirculation kinetics of TDL
(Smith & Ford, 1983), TDL for ricin labelling were collected
for a short term (4 h) period at room temperature (RT).
TDL was filtered through gauze, washed, counted and resus-
pended to 108 cells ml-' in RPMI + 10% foetal calf serum
(FCS) at 37°C. Ricin was added at 25tig 10-8 lymphocytes
and incubated for 15 min. Further internalisation of ricin was
inhibited by 100 mmol solution of lactose in RPMI + 10%
FCS at RT. The cells were washed twice in lactose-RPMI
medium and once in RPMI + 10% FCS at RT before final
resuspension to 108 cellsml' for injection.
Cell labelling with radioiodinated ricin enabled quantita-
tion of ricin uptake. The rate of ricin uptake was determined
by the regular removal of samples during a 4 h incubation
period. An incubation ricin concentration of 25Itg 10-8 cells
was found to be optimal since higher concentrations were
known to impair lymphocyte migration to LN, whilst lower
concentrations would have necessitated impractically large
numbers of TDL to provide a therapeutic dose (Sparshott et
al., 1985). Previous studies demonstrated that 1251-labelled
ricin was equal in toxicity to native ricin (Ramsden et al.,
1989.
Release ofricin and chromium-SIfrom lymphocytes
'25I-Ricin-loaded TDL were held in vitro at 37°C and ricin
release determined. Radioactivity detected in the supernatant
was expressed as a percentage of the total radioactivity per
sample. In the same way, an estimation of 5'Cr label released
from passaged TDL was made. The release of chromium is
indicative of cell death and is similar to that of a cytotoxic
release assay both in vitro and in vivo (Rolstad, 1985).
Tissue distribution ofradioactivity
Rats injected i.v. with free or cell associated '25I-ricin were
anaesthetised, a blood sample obtained by aortic puncture
and killed by aortic transection. Individual organs were
separated cleanly from adjacent structures, removed, weighed
and the amount of radioactivity determined by gamma count-
ing (LKB Ultragamma 1250 dual channel gamma spectro-
meter). Pulse height analyser facilities for each channel, and
automatic comparison for each channel with reference sam-
ples allowed discrimination between isotopes (5"Cr and 251)
when necessary. Results were expressed as a percentage of
the injected dose per gram to reflect the relative concentra-
tion in different tissues.
In vitro studies: inhibition ofprotein metabolism by ricin
Incorporation of 3H Leucine (Leu) 100fL aliquots of leu-
cine-free culture medium with or without ricin (37.5jigml-')
were distributed in a 96 well microtitre plate and incubated
at 37°C in the presence of 5% CO2. TDL (50 Ll of
5 x 106 ml-' in leucine-free medium) were added to each
well. Wells were pulsed with 3H Leu (10 iCiml1', Amer-
sham, Code No TRK 170, Specific activity 70 Ci mmol-'
leucine). Cell cultures were harvested at 10min intervals in
the first hour and at 1, 2, 3, and 5 h thereafter. 3H Leu
incorporation was measured by scintillation counting a Beck-
man counter (LS 1801).
Results
In vitro uptake ofricin by TDL
The uptake of ricin by cells was studied by incubating TDL
in RPMI + 10% FCS containing '251-ricin (25 yg 10-8 cells)
for varying periods. Less than 1% of the ricin was inter-
nalised (142 ng to 185 ng 10-8 cells) by 15 min (Figure 1).
Ricin incorporation followed an exponential curve, linear in
the first 15 min but levelling off at 30 min; increasing
amounts were internalised as late as 4 h.
Since galactose side chains present on serum proteins
might compete with cells for ricin binding, TDL were incu-
bated with '25I-ricin in a medium containing no FCS. Ricin
uptake was increased 4-5 fold (800 ng 10-8 cells, or 3.2% of
total). However as indicated later, the absence of protein in
the medium had a deleterious effect on lymphocyte migration
in vivo.
The distribution ofricinfollowing i.v. injection ofricin-loaded
TDL
The systemic distribution and kinetics of free '251I-ricin in rats
was reported previously (Ramsden et al., 1989). We com-
pared this distribution with that of 251I-ricin transported in
vivo by syngeneic TDL. In a number of tissues, notably
blood (both cell associated and plasma), heart, muscle and
bone marrow, the localisation of ricin, targeted by cells
(Table I) or injected free (Ramsden et al., 1989) was similar.
Tissues where significant differences in ricin distribution
resulted from the transport of ricin on cells are illustrated in
Figure 2. At 1 h the localisation of ricin carried to the liver
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Figure 1 Uptake of 25I-ricin by TDL in vitro. The results of two
separate experiments (e,*) are shown. Each point is the mean of
three samples removed from the incubation mixture.LYMPHOCYTE TARGETED RICIN 701
Table I Distribution of 125I conjugated ricin loaded lymphocytes
1, 2, 12 and 24h after injection into recipient animals. Percentage
injected dose per gram of tissue (standard deviation in parentheses)
Time (hours)
1 2 12 24
Blood cells 0.57 0.57 0.44 0.16
(0.11) (0.09) (0.18) (0.10)
Blood serum 1.14 0.84 0.74 0.13
(0.21) (0.08) (0.19) (0.04)
Heart 0.49 0.39 0.36 0.08
(0.14) (0.03) (0.05) (0.05)
Muscle 0.22 0.13 0.15 0.04
(0.15) (0.02) (0.01) (0.01)
Small gut 0.87 1.06 0.89 0.26
(0.28) (0.28) (0.25) (0.06)
Large gut 0.55 0.81 0.60 0.15
(0.03) (0.07) (0.11) (0.04)
MLN 5.22 6.64 4.20 0.76
(0.94) (0.62) (0.47) (0.25)
Bone marrow 5.60 5.91 2.09 0.77
(1.44) (1.82) (0.64) (0.32)
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1985). In these earlier experiments unlabelled ricin was
loaded into 5'Cr-labelled TDL and the ultimate distribution
ofricin was inferred from the distribution of51Cr. In order to
clarify the discrepancy a double-labelled experiment was
designed to allow for a direct comparison. I251-ricin was
loaded into passaged 51Cr-labelled TDL. These double-label-
led cells were injected into four groups of five animals each;
groups were killed at 4, 2, 12 and 24 h (Figure 3).
5'Cr tissue concentrations were used as an indicator of
localisation of the TDL. In comparison with published mi-
gration kinetics using 5"Cr TDL (Smith & Ford, 1983), the
ricin-loaded TDL localised in spleen and LN almost nor-
mally during the first 2 h after injection (Figure 3). The
migration pattern differed at subsequent periods in that ricin-
loaded TDL failed to be redistributed from spleen to LN,
reflecting the toxic effects of ricin on lymphocyte mobility.
Figure 3 shows an enormous discrepancy between 5"Cr and
'25I-ricin distribution. At I h spleen and lymph nodes con-
tained high 5"Cr levels, whereas "'I-ricin levels were only
50% and 30% of 51Cr values, respectively. The level of
localisation of 51Cr and 1251 was reversed in the liver (0.9%
5"Cr; 3.7% ricin), bone marrow (4.2% 5'Cr; 8% ricin), blood
(0.6% 5'Cr; 1.1% ricin) and kidney (0.3% 51Cr; 0.7% ricin).
Furthermore, while 51Cr tended to be retained in lymphoid
organs and the liver, '25I-ricin was rapidly eliminated after
2 h. These results indicate that ricin rapidly dissociated from
the lymphocytes after injection, even before they entered
lymphoid tissue. Ricin that was transported to lymphoid
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Figure 2 Organ distribution of free ricin (---) or ricin carried
by TDL (-) 1, 2, 6 and 12 h following i.v. injection. TDL were
labelled with "5I-ricin (25 sg 108ml-') and 10-8 cells injected.
Cell-free '25I-ricin was injected at I figkg-' body weight; data
obtained from parallel experiments using the same batch of ricin
but published elsewhere (Ramsden et al., 1989). Each point
represents the mean ± s.e. of five samples.
by TDL was 30% less than that resulting from i.v.-injection
of free ricin. This difference persisted over the next 12 h.
There was a doubling of the activity found in the lung at all
time intervals, reflecting lymphocyte entrapment within the
pulmonary vasculature. Renal localisation following injection
of ricin loaded lymphocytes was persistently half that result-
ing from use of free ricin. In lymphoid tissue we observed a
considerable concentration of ricin by targeting with TDL.
There was a doubling in the spleen, a 4-fold increase in the
cervical LN and 10-fold increase in Peyer's patches.
Simultaneous localisation of'251-ricin and"Cr by lymphocytes
In the above experiments the increase in lymphoid localisa-
tion of ricin, achieved by lymphocyte targeting, was con-
siderably less than that suggested previously (Sparshott et al.,
10'
a)
E co
CD
0)
a)
0
Co 0
'0 -0
a)
C.)
a)
0
0)
c
0)
a) 0)
a-
1
,.'"I ..f
., I...
lWN
a
1/2 2 12 24
Cervical
lymph node
10 -
1
-
-...
1/2 2 1224
Liver
Mesenteric
e lymph node
Spleen
LJ
Bone marrow
I..,
4
L J- LJ---
Kidney Lung Blood
Organ distribution at ½ 2 12 and 24 hours
Figure 3 Distribution of radioactivity in AO rats injected with
5'Cr labelled (---) passaged TDL loaded with '25I-ricin (-) and
killed at 1, 2, 12 and 24 h following i.v. injection. Each point is
the mean ± s.e. of five samples.
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tissues was retained for up to 2 h but then rapidly released.
In contrast 5"Cr was present for longer periods and released
at the time of cell death. It was estimated that about 70% of
transported ricin had dissociated from the cells within 0.5 h
of injection.
This early release of ricin seriously reduces the efficiency of
concentrating ricin in lymphoid tissue. Therefore, we have
investigated the early release of ricin and the effect ofricin on
TDL in vitro.
In vitro release of5'Cr and '25I-ricin
Passaged 5"Cr-labelled TDL, were loaded with 251I-ricin,
washed and incubated in suspension at 37°C. Samples were
removed at regular time intervals, centrifuged and both
supernatant and cell pellet counted. Release of ricin from
TDL in the first 20 min was rapid (Figure 4) and continued
but at a slower rate, so that by 120 min 60% had dissociated.
The loss of 51Cr during this period was minimal; 4% release
by 2 h. The in vivo release of ricin from TDL by half an hour
was 70%, although only 35% release was noted in vitro.
Effect ofricin on 51Cr TDL
The effect of ricin on 51Cr-TDL was studied by observing the
release of 51Cr in vitro during 24 h of culture. 51Cr-labelled
TDL were loaded (or not) with ricin, washed, incubated at
37°C and cultures sampled at intervals. The results of two
experiments are shown in Figure 5. During the first 2 h less
- 1251 Ricin-associated
- 51Cr Cell-associated
I~~~~~~
................ SI " ... .. ....
than 5% of 5"Cr was released from ricin-loaded TDL, but
with time the loss of 5"Cr from these cells increased faster
than the release from control cells. By 24 h 85% of5"Cr had
been released as a result of ricin loading compared with
45-50% from control cells. Maximum 51Cr release in vitro
occurred by 12-24 h correlating closely with the timing of
5'Cr loss from lymphoid tissues and its appearance in kidney
in the in vivo situation.
Rapid release ofricinfrom TDL
The in vitro incubation ofTDL loaded with ricin showed two
phases of release, an early exponential phase (first 40 min)
followed by a slow release phase (Figure 4). We asked
whether, by allowing the rapid phase to occur in vitro for
40 min before transfer, the selective localisation of ricin to
lymphoid tissues by TDL could be improved. Initially we
showed that in vitro incubated ricin TDL, when washed and
incubated in vitro for a further 40min, continued to release
ricin at a slow steady rate and did not revert to the rapid
release phase. Therefore, '25I-ricin-loaded TDL were tested in
vivo after receiving a 40 min incubation step. The 125_I
localisation from standard 1251-ricin TDL and the 40 min
incubated 125I-ricin TDL was no different (Table II). Allow-
ing an early in vitro elution of ricin did not prevent a further
elution of ricin in vivo, nor improve the targeting of ricin to
lymphoid tissue.
Effect ofricin on the kinetics ofprotein synthesis
In the following experiments the effect of ricin on protein
metabolism was examined in an attempt to determine whether
there was a correlation with loss of migratory ability, release
of ricin, or death of the cell. Protein synthesis was assessed
by 3H-leucine (3H-Leu) incorporation. 3H-Leu was added to
cultures of TDL, with or without added ricin (25 gml-').
Ricin free cultures incorporated 3H-Leu linearly from 5 min
to 5 h. The addition of ricin did not affect 3H-Leu incorpora-
tion during the first 40min, but by 60min, 3H-Leu incor-
poration had peaked at 70% of the ricin free culture. No
further incorporation was detected in the presence of ricin
during the subsequent 4 h (Figure 6).
Shortening the labelling time and its effect on lymphoid
targeting
12C
Time(mins)followingfinalwash and resuspension
Figure 4 In vitro release of 25I-ricin and 5"Cr from 5"Cr-labelled
TDL loaded with 251-ricin before incubation. Each point is the
mean ± s.d. of three samples.
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Figure 5 5'Cr release in vitro from 5'Cr-labelled TDL loaded
with ricin (25 fig 10-8 cells ml). Different symbols represent two
separate experiments. Each point is the mean of three samples.
o In view of the early inhibition of protein synthesis by ricin,
the handling time required to load ricin could be critical to
the success of ricin targeting in vivo. Using a revised protocol
in which the handling time was shortened from 60min to
21 min, we were unable to increase the proportion of 1251_
ricin delivered to LN or spleen in the I h period after injec-
tion (data not shown).
Discussion
Lymphocytes provide a powerful tool for targeting materials
to lymphoid tissue since, following injection into the blood-
stream, they localise in spleen and lymph nodes at a concen-
tration approximately 500 times greater than that averaged
over the whole body (Ford, 1985). Ninety percent of this
Table II The localisation in AO rats of '25I-ricin 1 h following i.v.
injection of'251-ricin loaded TDL prepared by the standard method or
incubated in vitro for40 minwith removal of'rapid release' ricin before
injection. Values(means ± s.e.)arepercentageofinjecteddosepergram
of tissue of three recipients in each group
'25I-ricin TDL
Tissue Standard method In vitro incubation
CLN 5.55 ±(0.35) 5.95 ±(2.0)
Liver 4.35 ± (0.05) 3.53 ± (0.4)
Spleen 53.0 (5.7) 50.9 +(2.5)
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Figure 6 Cumulative incorporation of 3H-Leu by TDL in culture
in the absence (control) or the presence of ricin (25 sgml').
Each point is the mean ± s.d. of three samples.
targeting is achieved within 1 h of injection, generating lym-
phoid concentrations 25,000 times that of non-lymphoid tis-
sues such as a muscle. We have clearly failed to achieve this
efficiency with ricin targeting by lymphocytes, but have
observed some success and identified the problem areas.
The first requisite of lymphocyte targeting is that the cells
should be able to take up the material concerned. In vitro
incubation with ricin results in lymphocyte-uptake of less
than 1% of the total ricin. This is not in itself a problem but
necessitates that, for clinical use, the ricin be trace-radio-
labelled in order to know precisely the dose which will be
administered to the recipient.
The second requisite is that ricin should not unduely affect
the migration properties of lymphocytes in the first hour or
so after injection. The quality of the lymphocytes is impor-
tant to this area since in vitro handling in itself reduces the
migratory potential of lymphocytes. Table III illustrates this
problem in conventional migration studies using 5"Cr as a
trace label. Overnight collection of TDL at 4C and subse-
quent in vitro manipulations of the trace-labelling process
severely inhibit migration to lymph nodes in particular
(Smith & Ford, 1983). Where we have had to use 5'Cr
labelled cells in our experiments we have first passaged them
from blood to lymph of a syngeneic intermediate animal to
overcome this problem. When not using 51Cr labelled cells we
have always used freshly collected TDL and avoided cooling
below RT or prolonged periods in vitro at 37°C which is also
detrimental to migratory properties (Smith & Ford, 1983). In
clinical studies it is fortunate that lymphocytes freshly-
isolated from peripheral blood are equally endowed with
good migratory properties (Wagstaff et al., 1981a,b). It is
also clear from the present results, especially Table III, that
neither the in vitro handling involved in loading lymphocytes
with ricin nor the toxicity of ricin itself significantly affect
early migration. This is perhaps surprising in the light of the
severe and early effects of ricin on protein synthesis by
lymphocytes and other cells (Olsnes et al., 1976), but never-
theless indicates that the observed shortfall in targeting
efficiency for ricin cannot be accounted for by failure of the
lymphocytes themselves to reach lymphoid tissues.
It is the dual labelling experiment with 251I-ricin 51Cr-
labelled passaged lymphocytes which has elucidated the
major problem of early in vivo release of ricin from their
lymphocytic vehicles before those lymphocytes reach lym-
phoid tissues (Figure 3). We calculate that this represents a
70% loss of carried ricin into the blood stream in the first
half hour after injection and equally a 70% reduction in
targeting efficiency.
Accordingly we studied elution of ricin from lymphocytes
in vitro and found the early half hour release of 35% to be
only half that observed in vivo and to be considerably less
thereafter. This higher in vivo elution might suggest different
mechanisms to those operating in vitro. Certainly our at-
tempts to overcome in vivo elution by prior washing off of
loosely bound ricin with galactose or by permitting a rapidly
excreted fraction of ricin to be lost in vitro before cell injec-
tion were unsuccessful. Cerundolo et al. (1987) loaded ricin
into T-lymphocytes (either obtained in mass mixed leucocyte-
tumour cell cultures or a virus-specific cytotoxic clone) and
successfully inhibited the growth of Maloney-murine sarcoma
virus induced tumours in vivo. Both populations of T-
lymphocytes released '251I-labelled ricin rapidly during the first
30min in vitro and at a constant and slower rate thereafter.
The release pattern was quantitatively and qualitatively very
similar to that found in the present study for rat TDL. Their
ricin loading and subsequent washing procedures were very
similar to ours and it is believed that the ricin released
represents previously internalised holotoxin. Whether ricin
was released faster in vivo than in vitro in this mouse system
was not identified. However the early release of ricin from
carrier lymphocytes in vivo presents the major obstacle to
further reducing systemic toxicity for a given therapeutic
effect.
The third requisite of lymphocyte targeting is that follow-
ing the arrival of lymphocytes in lymphoid tissue they should
transfer their contained load of toxin to surrounding cells,
preferably with a minimum of spillage into the blood stream.
In vitro studies have already demonstrated that ricin loaded
lymphocytes can transfer a lethal dose of toxin to other cells
in coculture (McIntosh et al., 1984). Studies of Sparshott et
al. (1985) indicate that this also happens with ricin targeting
by lymphocytes generating considerable histological damage
in lymphoid tissues. Our own histological findings are the
subject of a subsequent paper, but it is clear from the current
Table m Acomparison between the I hlocalisation ofTDLcollectedat4°C, labelledwith 5'Crand(1)used
immediately, (2) used after blood to lymph passage through an intermediate animal to allow full recovery of
migration abilities (passaged 5"Cr-TDL), (3) passaged 5'Cr-TDL loaded with '25l-ricin and used
immediately
Overnight TDL* Passaged TDL Ricin-loadedpassaged TDL
Localisation (Cell label) (Cell label) (Cell label) (Ricin label)
Isotope 51Cr 51Cr 51Cr 125I
Time after TDL 2 2 j 2 2 2
injection (h)
Liver 1.2t 1.1 1.0 0.6 0.9 1.0 3.7 3.0
Spleen 85 105 103 88 110 115 54 39
CLN 8.2t 9.4 36 59 23 29 6.8 6.9
*Rannie & Donald, (1977). tValues are percent injected dose per gm of tissue.704 C.S. RAMSDEN et al.
results that ricin is released from ricin loaded lymphocytes
albeit mostly at an early stage and systemically and not in
lymphoid tissue. The timing of that release is not particularly
related to the cessation of protein synthesis or to the final
death of the cells which, by 5'Cr studies both in vitro and in
vivo, probably occurs around 12 h after ricin loading. Ricin
which is carried into lymphoid tissues on carrier lymphocytes
reaches there within an hour of injection. Subsequent loss of
that ricin from lymphoid tissues occurs with identical kinetics
to those for free ricin (Figure 2). Whether this represents
direct loss from carrier lymphocytes into the blood stream or
includes an intermediate passage through surrounding cells is
uncertain but the similarity of the kinetics suggests the
former alternative to be quantitatively more important.
This work illustrates many of the potential pitfalls in using
lymphocytes to target materials in general and ricin in partic-
ular. We have identified the main reasons for the shortfall in
potential efficiency of lymphocyte targeted ricin, though un-
fortunately have not been able to overcome the problems
involved. Despite these limitations, distribution studies dem-
onstrated successful ricin targeting to lymphoid tissue, with a
4-fold increase in ricin delivered to LN, a 10-fold increase in
the Peyers patches, a doubling in the spleen and a 35%
reduction of ricin in the liver as compared to free ricin. Ricin
is an effective anti-tumour agent in both animal and human
tumours and lymphocyte targeting potentially provides a
method oftreating lymphoid malignancies or micrometastatic
lymph node spread from solid tumours.
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